Genetic causes of neurodevelopmental disorders: Insights from trio exome sequencing

Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

Neurodevelopmental disorders (NDDs) have diverse genetic origins, making diagnosis challenging. A new study analysing over 1,100 pediatric patients found that trio-exome sequencing (trio-ES) identified both single-nucleotide variations (SNVs) and copy number variants (CNVs), achieving a 46.1% diagnostic yield. Notably, trio-ES detected small CNVs that traditional methods might miss, highlighting its value in genetic testing. These findings reinforce the clinical utility of trio-ES for improving diagnostic precision in children with NDDs, enabling better-informed patient care and management. Read more about this under Article 1 below.

Article 1: Diagnostic utility of trio–exome sequencing for children with neurodevelopmental disorders

A study of 1,106 pediatric patients with neurodevelopmental disorders found that trio-exome sequencing, which detects both single-nucleotide variants (SNVs) and copy number variants (CNVs), achieved a 46.1% diagnostic yield. This approach enhances genetic testing by identifying small CNVs and recessive conditions, improving diagnostic accuracy in clinical practice. Read the full article .

In summary: Trio-exome sequencing improves pediatric neurodevelopmental disorder diagnosis

Article 2: High-throughput screening of human genetic variants by pooled prime editing

A new prime editing platform enables large-scale functional testing of human genetic variants in their natural genomic context. Using improved editing efficiency and selection strategies, researchers identified novel loss-of-function variants in SMARCB1 and MLH1. This approach enhances the discovery of pathogenic variants in both coding and non-coding regions. Read the full article .

In summary: Prime editing enables large-scale genetic variant testing

Article 3: Spatially resolved mapping of cells associated with human complex traits

A new method, gsMap, integrates spatial transcriptomics with genetic data to map disease-associated cells. Applied to brain disorders, it reveals that schizophrenia-related neurons are spatially distinct from depression-related ones, highlighting differences in gene expression. This approach enhances understanding of disease pathology through spatially resolved genetic insights. Read the full article .

In summary: gsMap maps disease cells for better brain disorder insights

Article 4: Proteome-wide assessment of differential missense variant clustering in neurodevelopmental disorders and cancer

Researchers analysed genetic variants in 3D protein structures, identifying 37 proteins with distinct missense mutation clustering in neurodevelopmental disorders (NDDs) and cancer. This method enhances understanding of shared disease mechanisms and may inform future prognostic and therapeutic strategies. Read the full article .

In summary: Missense variant clustering linked to neurodevelopmental disorders and cancer

Article 5: Low frequency of structured documentation for cancer genetic testing in a large electronic health record dataset: A brief report using All of Us Research data

Despite guidelines recommending genetic testing for many cancer patients, completion rates remain low. A study using the All of Us database found only 281 out of 60,135 eligible individuals had documented genetic tests. Improved genetic data standardisation in electronic health records is crucial for better access and research advancements. Read the full article .

In summary: Low genetic testing documentation for cancer in electronic records

Last updated: 14.09.2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases
  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • ebiom+

    A comprehensive assessment of the endometrial microbiome and chronic endometritis pathogens to enhance clinical outcomes, prevent treatment delays, and support a more informed, personalised fertility care.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- and CLIA- and ISO15189 accredited, GMP- and ISO9001 and 13485 certified

Are you a patient?

Are you a physician?